JHU's Neurofibromatosis Therapeutic Acceleration Program celebrated the 10th anniversary of its Francis S. Collins Scholars ...

The new approval will help Merck make a return on its $3.9 billion investment in acquiring SpringWorks, which has operated as ...

A new study led by Indiana University School of Medicine researchers revealed a potential strategy to address neurobehavioral challenges associated with neurofibromatosis type 1, or NF1, a genetic ...

The European Commission (EC) has granted conditional approval to SpringWorks Therapeutics’ Ezmekly (mirdametinib) to treat ...

The European Commission has approved EZMEKLY (mirdametinib) for treatment of symptomatic, inoperable plexiform neurofibromas ...

EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) ...

A new study led by Indiana University School of Medicine researchers revealed a potential strategy to address neurobehavioral ...

The event, hosted by NF Network, included a 5K walk/run, a basket raffle and a time to share and spread awareness ...

The European Commission granted conditional marketing authorization for Ezmekly (mirdametinib) for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in pediatric and adult patients ...

Exposure to higher levels of air pollution over time was tied to a higher risk of meningioma, a type of brain tumour that is not usually cancerous but can cause other health problems.

SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that the European Commission (EC) granted conditional marketing authorization ...

Merck KGaA said its Ezmekly therapy for people with a rare genetic disorder has received the conditional marketing approval from the European Commission. The pharmaceutical company said Friday that ...